197 related articles for article (PubMed ID: 33414400)
1. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
Rosenberg AS; Brunson A; Tuscano J; Jonas BA; Hoeg R; Wun T; Keegan THM
Blood Cancer J; 2021 Jan; 11(1):5. PubMed ID: 33414400
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
3. Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.
Rosenberg AS; Brunson A; Jonas BA; Keegan THM; Wun T
J Natl Cancer Inst; 2019 Jan; 111(1):78-85. PubMed ID: 29897481
[TBL] [Abstract][Full Text] [Related]
4. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
[TBL] [Abstract][Full Text] [Related]
5. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H; Matsuda T; Mizuno S; Takahashi T; Fuchida SI; Hanamura I; Kataoka K; Tsukada N; Matsumoto M; Hangaishi A; Doki N; Uchida N; Sawa M; Maruyama Y; Kurahashi S; Nagafuji K; Harazaki Y; Kako S; Iida S; Ichinohe T; Kanda Y; Atsuta Y; Sunami K;
Haematologica; 2023 Dec; 108(12):3399-3408. PubMed ID: 37470160
[TBL] [Abstract][Full Text] [Related]
6. The limited use of autologous hematopoietic stem cell transplant for fit older patients with multiple myeloma in India: a retrospective analysis.
Revannasiddaiah S; Nagaraju PRVMA; Palassery R; Jagadish A; Maka VV; Kilara N; Rondelli D; Devadas SK
J Egypt Natl Canc Inst; 2022 May; 34(1):21. PubMed ID: 35570260
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
8. Secondary primary malignancies in patients with multiple myeloma: A single institution experience.
Fei F; Reddy V; Rosenblum F
Hematol Oncol; 2021 Dec; 39(5):674-679. PubMed ID: 34510500
[TBL] [Abstract][Full Text] [Related]
9. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Krishnan AY; Mei M; Sun CL; Thomas SH; Teh JB; Kang T; Htut M; Somlo G; Sahebi F; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Feb; 19(2):260-5. PubMed ID: 23073267
[TBL] [Abstract][Full Text] [Related]
10. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
11. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Yamasaki S; Yoshimoto G; Kohno K; Henzan H; Aoki T; Tanimoto K; Sugio Y; Muta T; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Miyamoto T; Akashi K; Iwasaki H;
Int J Hematol; 2019 Jan; 109(1):98-106. PubMed ID: 30251131
[TBL] [Abstract][Full Text] [Related]
12. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
13. Second primary malignancies in multiple myeloma: A review.
Poh C; Keegan T; Rosenberg AS
Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
[TBL] [Abstract][Full Text] [Related]
14. [Complications of successively double autologous hemopoietic stem cell transplants].
Huang WR; Da WM; Zhang BL; Gao CJ; Han XP; Jing Y; Wu XX; Zhao Y; Li HH; Wang QS; Zhang YZ; Bo J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):30-4. PubMed ID: 15748431
[TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice.
Miceli T; Lilleby K; Noonan K; Kurtin S; Faiman B; Mangan PA
Clin J Oncol Nurs; 2013 Dec; 17 Suppl():13-24. PubMed ID: 24280455
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation for multiple myeloma.
Bensinger WI
Biomed Pharmacother; 2002 May; 56(3):133-8. PubMed ID: 12046684
[TBL] [Abstract][Full Text] [Related]
17. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Ragon BK; Shah MV; D'Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS; Banerjee R; Saad A; Hildebrandt GC; Mian H; Abid MB; Battiwalla M; Lekakis LJ; Patel SS; Murthy HS; Nieto Y; Strouse C; Badawy SM; Al Hadidi S; Dholaria B; Aljurf M; Vesole DH; Lee CH; Pawarode A; Gergis U; Miller KC; Holmberg LA; Afrough A; Solh M; Munshi PN; Nishihori T; Anderson LD; Wirk B; Kaur G; Qazilbash MH; Shah N; Kumar SK; Usmani SZ
Blood Adv; 2023 Jun; 7(12):2746-2757. PubMed ID: 36827681
[TBL] [Abstract][Full Text] [Related]
18. Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma.
Rahman S; Rybicki L; Ky Hamilton B; Pohlman B; Jagadeesh D; Cober E; Kalaycio M; Dean R; Sobecks R; Mossad SB; Majhail NS
Transpl Infect Dis; 2019 Aug; 21(4):e13114. PubMed ID: 31102556
[TBL] [Abstract][Full Text] [Related]
19. Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018.
Wang J; Lv C; Zhou M; Xu JY; Chen B; Wan Y
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230842
[TBL] [Abstract][Full Text] [Related]
20. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]